Third Line Trials

1. Study of Safety and Efficacy of EGF816 in Combination With INC280 in Non-small Cell Lung Cancer Patients With EGFR Mutation

      ClinicalTrials.gov Identifier:             NCT02335944      

The study determines the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of EGF816 in combination with INC280 and to estimate the preliminary anti-tumor activity of EGF816 in combination with INC280 in patients with advanced non-small cell lung cancer (NSCLC) with documented EGFR mutation.

Alberta
Edmonton, Alberta, T6G 1Z2
 

2. BMS-986012 in Relapsed/Refractory SCLC

      ClinicalTrials.gov Identifier:             NCT02247349      

The purpose of this study is to determine the safety, tolerability, pharmacokinetics,immunogenicity,antitumor activity and pharmacodynamics of BMS-986012 in subjects with relapsed/refractory SCLC.

Alberta
Cross Cancer Institute, Edmonton

Ontario
Princess Margaret Hospital, Toronto 
 

3. Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

      ClinicalTrials.gov Identifier:             NCT02393625      

This is an open label multi center trial to determine the safety and efficacy of ceritinib in combination with nivolumab in ALK-positive NSCLC patients.

Ontario 
Toronto, Ontario, M5G 2M9 


4. ELUXA 1: Phase II Trial of HM61713 (BI 1482694) for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung

      ClinicalTrials.gov Identifier:             NCT02485652      
 
This study is ongoing, but not recruiting participants. 
 
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of HM61713 (BI 1482694) in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).

Ontario 
Toronto 

Quebec
Montreal 
 

5. Sapanisertib and Osimertinib in Treating Patients With Stage IV EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor

      ClinicalTrials.gov Identifier:              NCT02503722      
 
This phase I trial studies the side effects and best dose of sapanisertib when given together with osimertinib in treating patients with stage IV EGFR mutation positive non-small cell lung cancer that has progressed after treatment with an EGFR tyrosine kinase inhibitor. Sapanisertib and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
 
British Columbia
BCCA-Vancouver Cancer Centre Recruiting
Vancouver, British Columbia, Canada, V5Z 4E6
Contact: Site Public Contact, 888-939-3333      
Principal Investigator: Cheryl Ho   
     
Ontario
University Health Network-Princess Margaret Hospital Recruiting
Toronto, Ontario, Canada, M5G 2M9
Contact: Site Public Contact, 416-946-4501   clinical.trials@uhn.on.ca   
Principal Investigator: Penelope A. Bradbury     


6. A Study to Test Combination Treatments in People With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)

      ClinicalTrials.gov Identifier:             NCT02750514      

The purpose of this study is to determine whether nivolumab in combination with other therapies is more effective than nivolumab alone in people with advanced Lung cancer.

Alberta
Edmonton

Ontario 
Ottawa
 

7. Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer

      ClinicalTrials.gov Identifier:              NCT02414139      

A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC).

Ontario 
Novartis Investigative Site
Ottawa, Ontario,  K1H 8L6


8. A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC

       ClinicalTrials.gov Identifier:              NCT02387216      

The purpose of this study is to determine whether the combination of MM-121 plus docetaxel or pemetrexed is more effective than docetaxel or pemetrexed alone in regards to OS in patients with heregulin-positive NSCLC.
 
Ontario 
Toronto 

9. A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

      ClinicalTrials.gov Identifier:              NCT02108964      

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies
 
Ontario 
Toronto
 

10. An Efficacy Study Comparing Brigatinib Versus Alectinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung CancerParticipants Who Have Progressed on Crizotinib (ALTA-3)

      ClinicalTrials.gov Identifier:             NCT03596866      

The purpose of this study is to compare the efficacy of brigatinib versus alectinib in participants with anaplastic lymphoma kinase-positive (ALK+) locally advanced or metastatic non-small-cell lung cancer (NSCLC) who have progressed on crizotinib as evidenced by progression free survival as assessed by a blinded independent review committee (BIRC) utilizing response evaluation criteria in solid tumors (RECIST) v1.1.

Nova Scotia 
Queen Elizabeth II Health Sciences Centre           Not yet recruiting
Halifax, Nova Scotia, Canada, B3H 1V7 
 
 
Ontario
Toronto University Health Network Not yet recruiting
Toronto, Ontario, Canada, M5G 2M9


11. Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST)

      ClinicalTrials.gov Identifier:             NCT03822351      

The purpose of this study is to compare the clinical activity of durvalumab alone vs durvalumab in combination with novel agents. The overall study goal is early identification of novel durvalumab combinations that are more active than durvalumab alone in the treatment of patients with unresectable, Stage III NSCLC who have not progressed after cCRT.
 
Alberta
Research Site                                                Not yet recruiting
Edmonton, Alberta, Canada, T6G 1Z2
 
Ontario
Research Site                                                Not yet recruiting
Toronto, Ontario, Canada, M5G 2M9

12. Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

      ClinicalTrials.gov Identifier:             NCT03377556      

 
This phase II trial studies how well talazoparib works in treating patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer that has come back after previous treatment. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
 
Alberta
Cross Cancer Institute                             Active, not recruiting
Edmonton, Alberta, Canada, T6G 1Z2
 
Ontario
Juravinski Cancer Centre at Hamilton Health Sciences                             Active, not recruiting
Hamilton, Ontario, Canada, L8V 5C2
 
Ottawa Hospital and Cancer Center-General Campus                             Active, not recruiting
Ottawa, Ontario, Canada, K1H 8L6
 
University Health Network-Princess Margaret Hospital                             Active, not recruiting
Toronto, Ontario, Canada, M5G 2M9
 
Saskatchewan
Allan Blair Cancer Centre                              Active, not recruiting
Regina, Saskatchewan, Canada, S4T 7T1
 
Saskatoon Cancer Centre                             Active, not recruiting
Saskatoon, Saskatchewan, Canada, S7N 4H4


13. A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (ALTA-2)

      ClinicalTrials.gov Identifier:              NCT03535740      

The primary purpose of this study is to determine the efficacy of brigatinib by confirmed objective response rate (ORR) by response evaluation criteria in solid tumors (Response Evaluation Criteria in Solid Tumors [RECIST]), in participants with ALK+ locally advanced or metastatic NSCLC whose disease has progressed on therapy with alectinib or ceritinib.
 
Alberta
Cross Cancer Institute                                                   Recruiting
Edmonton, Alberta, Canada, T6G 1Z2
 
British Columbia
Tom Baker Cancer Center                                                   Recruiting
Calgary, British Columbia, Canada, T2N 2T9
 
Ontario
Toronto University Health Network                                                   Not yet recruiting
Toronto, Ontario, Canada, M5G 2M9
 
Quebec
McGill University Health Centre                                                   Recruiting
Montreal, Quebec, Canada, H4A 3J1

14. Phase II Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Non-small Cell Lung Cancer (NSCLC)

 
      ClinicalTrials.gov Identifier:              NCT03739710      

This study will compare the clinical activity of novel immune-oncology agents (in combination or as single agents) to standard of care in participants with relapsed/refractory advanced NSCLC. The study will initially evaluate two treatment regimens/arms. Additional regimens/arms may be added via future protocol amendment(s). Participants will be stratified by histology (squamous vs. non-squamous) and line of anti-programmed cell death ligand 1 (PD[L]1) therapy (first vs. second line). Initially, the study will evaluate the GSK3359609 inducible T-cell co-stimulator (ICOS) agonist in combination with SoC docetaxel compared to docetaxel alone (sub-study 1). SoC arm will be the common comparison arm across all sub-studies. At study start, subjects will be randomized to the study at a ratio of 1:2 to Arm 1 (docetaxel) and Arm 2 (ICOS agonist + docetaxel). The study will consist of three periods: Screening, Treatment, and Follow-Up. There will be approximately 105 participants enrolled in the study initially. Treatment will continue for approximately 2 years and participants will be followed for survival during the follow-up period.
 
Alberta
GSK Investigational Site                                                                            Recruiting
Edmonton, Alberta, Canada, T6G 1Z2
Contact: US GSK Clinical Trials Call Center,  877-379-3718
GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre,   
+44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Quincy Chu         
 
Ontario
GSK Investigational Site                                                                            Recruiting
Brampton, Ontario, Canada, L6R 3J7
Contact: US GSK Clinical Trials Call Center,  877-379-3718 
GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre,
+44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Parneet Cheema   
     
GSK Investigational Site                                                                            Recruiting
Ottawa, Ontario, Canada, K1H 8L6
Contact: US GSK Clinical Trials Call Center,  877-379-3718
GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre,
+44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Paul Wheatley-Price   
     
GSK Investigational Site                                                                            Recruiting
Toronto, Ontario, Canada, M5G 2M9
Contact: US GSK Clinical Trials Call Center,  877-379-3718 
GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre,  
+44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com